Autolus Therapeutics plc
Research Autolus Therapeutics plc (AUTL) on Bullrun: market cap USD 439.14M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAUTL
- ExchangeNASDAQ
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 439.14M
- Financial periodFY2025
- RevenueUSD 75.39M
- Revenue growth644.9%
- Net income-USD 287.53M
- Free cash flow-USD 302.61M
- Gross margin-27.8%
Valuation Snapshot
latest market cap is USD 439.14M.
About Autolus Therapeutics plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.
Frequently asked questions
What is Autolus Therapeutics plc's market cap?
Autolus Therapeutics plc's market capitalization is USD 439.14M.
What does Autolus Therapeutics plc do?
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally.